Multiple Sclerosis | Emerging Therapies | Zinbryta (daclizumab) | US | Wave 2 | 2017
With its launch in August 2016, Zinbryta became the 14th disease-modifying therapy (DMT) approved to treat relapsing forms of multiple sclerosis (MS) in the United States. The monoclonal antibody boasts solid efficacy, infrequent dosing, and a novel anti-inflammatory mechanism of action, but the potential for serious long-term side effects has led to a restrictive U.S. label. DRG’s launch-tracking series will examine how the perception and performance of Zinbryta evolves through one year postlaunch in an MS market that, on the one hand, is increasingly transformed by a growing array of DMTs with compelling risk-benefit profiles, but on the other hand, can and will support a clinical role for each new agent in treating a heterogeneous disease with a complex natural history.
What you will learn in this content:
- What is U.S. neurologists’ awareness of and familiarity with Zinbryta, and what are their perceptions of the product?
- Among prescribers, for which patients are they prescribing Zinbryta, what are the reasons for prescribing, and how satisfied are they with Zinbryta?
- What are the promotional messages and activities that Biogen/AbbVie are employing in support of the Zinbryta launch?
- How do prescribers and nonprescribers compare across key metrics?
- How is the trial and adoption of Zinbryta tracking compared with other product launches in the MS market?
Methodology: ~75-100 U.S. neurologists complete a 30-minute online quantitative survey with several open-ended questions for qualitative feedback. In addition, ten surveyed specialists participate in a 30-minute follow-up qualitative interview.
Key drugs: Zinbryta, Lemtrada, Tysabri, Ocrevus, Gilenya, Tecfidera, Copaxone, beta-interferons
Key companies: Biogen, AbbVie, Sanofi Genzyme, Novartis, Teva, Roche/Genentech
Related reports: Emerging Therapies Zinbryta Wave 1, Emerging Therapies Lemtrada Waves 1-4
